Abbott Kaletra Tops 12% Of PI Market; Synthroid Outlook Is "Very Good"

Abbott expects to claim the number one spot in the protease inhibitor market by the end of 2001 on the strength of the first-year performance of Kaletra (ritonavir/lopinavir).

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet